Hormonal
In a mixed population of diabetic and non-diabetic patients, liraglutide (up to 3 mg) and semaglutide (up to 1 mg) produce statistically equivalent weight loss, contradicting findings from trials using higher doses or specific diabetic cohorts.
If you are using liraglutide or semaglutide at lower, standard starting-to-maintenance doses (up to 3mg and 1mg respectively), expect similar weight loss results. The perceived superiority of semaglutide in marketing often relies on higher doses (2.4mg) not used in this study. Focus on adherence and titration rather than switching solely for weight loss efficacy at these doses.
When comparing the weight loss achieved in each group, liraglutide achieved a median weight loss of −4 (−7 to 0) kg versus −3 (−6 to 0) kg for semaglutide (P = 0.867)... Multivariable linear regression analysis confirmed no significant difference between the drugs [B −0.577, 95% CI −1.87 to 0.7; P = 0.38]... Conclusion: Both liraglutide and semaglutide were effective in reducing weight, with no significant difference between the two drugs.
Why this rating
Retrospective observational cohort study with a relatively small sample size (n=366) and shorter follow-up for semaglutide, limiting statistical power to detect differences.
Source
Comparing the Efficacy of Liraglutide and Semaglutide on Weight Loss: Experience from the Middle East Gulf Region and Literature Review
Wasim S. El Nekidy et al. · Hospital Pharmacy · 2025
DOI 10.1177/00185787251340645
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →